NEW YORK (GenomeWeb) – Bayer and Leica Biosystems said today they will collaborate on the development of a companion diagnostic that employs immunohistochemistry and RNAscope, a multiplex nucleic acid hybridization technology, to test cancer tissue.

Financial terms of the agreement were not disclosed.

Under the terms of the deal, Leica will provide expertise in assay development, regulatory approval, and commercialization of companion diagnostic tests for targeted anticancer therapies developed by Bayer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.